Association of the non-HDL cholesterol to HDL cholesterol ratio with possible sarcopenic obesity in Chinese adults.

Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE

Original Publication: London : Nature Publishing Group, copyright 2011-

Obesity*/blood ; Obesity*/epidemiology ; Cholesterol, HDL*/blood ; Sarcopenia*/blood ; Sarcopenia*/epidemiology ; Cholesterol*/blood; China/epidemiology ; Biomarkers/blood ; Humans ; Male ; Female ; Middle Aged ; Aged ; Longitudinal Studies ; Risk Factors ; Prevalence ; East Asian People

Sarcopenic obesity (SO) is a major public health concern linked to lipid metabolism disorders. This study investigated the association between the non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio (NHHR) and possible SO prevalence in China using data from the 2015 China Health and Retirement Longitudinal Study (CHARLS). Among 3,320 participants(21.02% men; median age 66.00 years [interquartile range, IQR 62.00-71.00]), multivariate logistic regression revealed that individuals in the highest NHHR tertile had a 66% increased risk of possible SO compared to the lowest tertile. Restricted cubic spline analysis identified a significant nonlinear relationship (p < 0.05). A two-piecewise regression model showed that for NHHR < 3.262, the adjusted odds ratio (OR) for possible SO was 2.27 (95% CI, 1.48-3.45; p < 0.001), whereas for NHHR ≥ 3.262, the OR was 0.97 (95% CI, 0.78-1.21; p = 0.78). This finding suggests that NHHR could serve as a novel and convenient biomarker for possible SO risk stratification; maintaining an NHHR below 3.262 may be a valuable target for preventing possible SO in the middle-aged and elderly Chinese population.
(© 2025. The Author(s).)

Declarations. Competing interests: The authors declare no competing interests. Ethics statement: CHARLS study is an open dataset. The CHARLS was approved by the Ethics Review Committee of Peking University (IRB 00001052–11015) and all participants signed an informed consent.

J Am Med Dir Assoc. 2020 Mar;21(3):300-307.e2. (PMID: 32033882)
Int J Obes (Lond). 2009 Aug;33(8):885-92. (PMID: 19564878)
Clin Nutr. 2021 Jul;40(7):4633-4641. (PMID: 34229269)
Front Nutr. 2025 Feb 28;12:1548851. (PMID: 40093879)
Lipids Health Dis. 2024 Aug 28;23(1):274. (PMID: 39198823)
Diabetes Metab Syndr Obes. 2020 Aug 25;13:3089-3097. (PMID: 32922058)
Front Endocrinol (Lausanne). 2020 May 21;11:332. (PMID: 32508753)
Clin Nutr. 2021 Jun;40(6):4422-4429. (PMID: 33485705)
J Cachexia Sarcopenia Muscle. 2017 Apr;8(2):251-258. (PMID: 27896949)
Int J Mol Sci. 2020 Mar 12;21(6):. (PMID: 32178449)
Lipids Health Dis. 2024 May 21;23(1):151. (PMID: 38773578)
J Diabetes Complications. 2023 Dec;37(12):108634. (PMID: 37918178)
J Ren Nutr. 2023 Jan;33(1):147-156. (PMID: 35597322)
Lancet. 2004 Jan 10;363(9403):157-63. (PMID: 14726171)
Metabolites. 2024 May 27;14(6):. (PMID: 38921440)
Prev Med Rep. 2025 Jun 26;56:103151. (PMID: 40678812)
Curr Atheroscler Rep. 2023 Dec;25(12):947-955. (PMID: 37979064)
Front Public Health. 2025 Apr 30;13:1585986. (PMID: 40371274)
J Am Geriatr Soc. 2007 May;55(5):769-74. (PMID: 17493199)
Ageing Res Rev. 2024 Jan;93:102164. (PMID: 38103840)
Nat Rev Endocrinol. 2024 May;20(5):261-277. (PMID: 38321142)
J Endocr Soc. 2024 Feb 02;8(3):bvae016. (PMID: 38370441)
Lipids Health Dis. 2025 Mar 25;24(1):112. (PMID: 40133921)
Exp Gerontol. 2025 Feb;200:112680. (PMID: 39793630)
Front Nutr. 2025 Apr 11;12:1452512. (PMID: 40290665)
J Cachexia Sarcopenia Muscle. 2021 Dec;12(6):2187-2198. (PMID: 34676673)
J Nutr Health Aging. 2020;24(4):429-437. (PMID: 32242211)
Diabetes. 2019 Jan;68(1):18-20. (PMID: 30573676)
Arch Osteoporos. 2018 Jun 9;13(1):65. (PMID: 29886557)
Front Nutr. 2024 Nov 28;11:1492191. (PMID: 39668900)
Front Cardiovasc Med. 2025 Jan 10;11:1524465. (PMID: 39866802)
Ageing Res Rev. 2017 May;35:200-221. (PMID: 27702700)
Clin Nutr. 2023 Oct;42(10):2051-2057. (PMID: 37677910)
Methods. 2022 Jul;203:179-186. (PMID: 32987130)
FASEB J. 2020 Mar;34(3):4684-4701. (PMID: 32030813)
Clin Nutr. 2022 Dec;41(12):2740-2748. (PMID: 36370663)
J Atheroscler Thromb. 2022 Sep 1;29(9):1295-1306. (PMID: 34690212)
Int J Epidemiol. 2014 Feb;43(1):61-8. (PMID: 23243115)
Front Psychiatry. 2024 Nov 05;15:1467142. (PMID: 39564464)

Keywords: CHARLS database; Dyslipidemia; Lipid metabolism; NHHR; Sarcopenic obesity

0 (Cholesterol, HDL)
0 (Biomarkers)
97C5T2UQ7J (Cholesterol)

Date Created: 20251125 Date Completed: 20251230 Latest Revision: 20260427

20260427

PMC12749443

10.1038/s41598-025-29858-7

41291008